Ibrutinib Fails in High-Risk Early-Stage CLL



Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.
Medscape Medical News



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *